Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

被引：0
|
作者：
Robin L. Jones
Gary Mo
John R. Baldwin
Patrick M. Peterson
Robert L. Ilaria
Ilaria Conti
Damien M. Cronier
William D. Tap
机构：
[1] University of Washington and Fred Hutchinson Cancer Research Center,
[2] Eli Lilly and Company,undefined
[3] Lilly Corporate Center,undefined
[4] Eli Lilly and Company,undefined
[5] Lilly Research Centre,undefined
[6] Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College,undefined
[7] Royal Marsden Hospital and Institute of Cancer Research,undefined
[8] Celgene,undefined
[9] EMD Serono Research & Development Institute,undefined
[10] Merck Serono Ltd,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Olaratumab; Doxorubicin; Exposure response; Outcome; Soft tissue sarcomas;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：191 / 199
页数：8
相关论文
共 50 条
  • [31] Efficacy and safety of anlotinib combined with liposomal doxorubicin in first-line treatment of advanced soft-tissue sarcoma.
    Sun, Xin
    Guo, Wei
    Zhang, Ranxin
    Xie, Lu
    Xu, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Trends in Survival for Patients With Metastatic Soft-Tissue Sarcoma
    Italiano, Antoine
    Mathoulin-Pelissier, Simone
    Le Cesne, Axel
    Terrier, Philippe
    Bonvalot, Sylvie
    Collin, Francoise
    Michels, Jean-Jacques
    Blay, Jean-Yves
    Coindre, Jean-Michel
    Bui, Binh
    CANCER, 2011, 117 (05) : 1049 - 1054
  • [33] Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
    Tap, William D.
    Jones, Robin L.
    Van Tine, Brian A.
    Chmielowski, Bartosz
    Elias, Anthony D.
    Adkins, Douglas
    Agulnik, Mark
    Cooney, Matthew M.
    Livingston, Michael B.
    Pennock, Gregory
    Hameed, Meera R.
    Shah, Gaurav D.
    Qin, Amy
    Shahir, Ashwin
    Cronier, Damien M.
    Ilaria, Robert, Jr.
    Conti, Ilaria
    Cosaert, Jan
    Schwartz, Gary K.
    LANCET, 2016, 388 (10043): : 488 - 497
  • [34] Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
    Aoyama, Takeshi
    Nakano, Kenji
    Yuasa, Takeshi
    Sugiyama, Erika
    Okawa, Takako
    Ito, Kazuyuki
    Azuma, Keiichi
    Hashimoto, Koki
    Furutani, Ryota
    Hiraide, Makoto
    Kobayashi, Kazuo
    Suzuki, Kenichi
    Tomomatsu, Jyunnichi
    Tajima, Masataka
    Sato, Hitoshi
    Hama, Toshihiro
    Takahashi, Shunji
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [35] Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
    Takeshi Aoyama
    Kenji Nakano
    Takeshi Yuasa
    Erika Sugiyama
    Takako Okawa
    Kazuyuki Ito
    Keiichi Azuma
    Koki Hashimoto
    Ryota Furutani
    Makoto Hiraide
    Kazuo Kobayashi
    Kenichi Suzuki
    Jyunnichi Tomomatsu
    Masataka Tajima
    Hitoshi Sato
    Toshihiro Hama
    Shunji Takahashi
    Scientific Reports, 13
  • [36] The efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcoma
    Ni, Ying
    Dong, Yabing
    Jiang, Aijun
    Zhang, Qun
    Wang, Zhantong
    Liang, Hui
    Zhang, Wei
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [37] Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma
    Van Tine, Brian A.
    Hirbe, Angela C.
    Oppelt, Peter
    Frith, Ashley E.
    Rathore, Richa
    Mitchell, Joshua D.
    Wan, Fei
    Berry, Shellie
    Landeau, Michele
    Heberton, George A.
    Gorcsan, John
    Huntjens, Peter R.
    Soyama, Yoku
    Vader, Justin M.
    Alvarez-Cardona, Jose A.
    Zhang, Kathleen W.
    Lenihan, Daniel J.
    Krone, Ronald J.
    CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3854 - 3860
  • [38] A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.
    Livingston, Michael B.
    Jagosky, Megan
    Robinson, Myra M.
    Ahrens, William
    Benbow, Jennifer H.
    Farhangfar, Carol J.
    Foureau, David
    Maxwell, Deirdre
    Baldrige, Emily
    Steuerwald, Nury
    Anderson, Colin J.
    Patt, Joshua
    Kneisl, Jeffrey
    Kim, Edward S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] DOXORUBICIN CHEMOTHERAPY IN THE TREATMENT OF SOFT-TISSUE SARCOMA - COMBINED RESULTS OF 2 RANDOMIZED TRIALS
    WILSON, RE
    WOOD, WC
    LERNER, HL
    ANTMAN, K
    AMATO, D
    CORSON, JM
    PROPPE, K
    HARMON, D
    CAREY, R
    GREENBERGER, J
    SUIT, H
    ARCHIVES OF SURGERY, 1986, 121 (11) : 1354 - 1359
  • [40] Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study
    Bonvalot, Sylvie
    Wunder, Jay
    Gronchi, Alessandro
    Broto, Javier Martin
    Turcotte, Robert
    Rastrelli, Marco
    Papai, Zsuzsanna
    Radaelli, Stefano
    Lindner, Lars H.
    Shumelinsky, Felix
    Cubillo, Antonio
    Rutkowski, Piotr
    Demaire, Clementine
    Strens, Danielle
    Nalbantov, Georgi
    EJSO, 2021, 47 (08): : 2166 - 2172
12345